Jeffrey Leiden

Last updated
Jeffrey Leiden
Jeffrey Leiden Portrait.jpg
Born
Glencoe, Illinois
NationalityAmerican
Alma mater University of Chicago
Occupation(s)Executive Chairman, Vertex Pharmaceuticals
Organizations
Board member of
Awards
Website Jeffrey Leiden

Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. [1] He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020. [2] [3]

Contents

Early life

Leiden grew up in Glencoe, a suburb north of Chicago. His mother was a primary school teacher, and his father was a clinical psychologist with a PhD in psychology. He has one sister. His grandparents on his mother’s side were Russian immigrants. At ten years old he learned to scuba dive, and by eleven he was a certified scuba instructor. [4]

Education

Leiden attended a progressive public school in Glencoe, IL called North School which had a special self-paced learning program. In elementary school Leiden skipped second grade and started the University of Chicago after his junior year at New Trier East High School, at the age of 15. [4]

He received his bachelor's degree in biological sciences at age 18, a Ph.D. in virology at age 21 and his M.D. at age 23 from the University of Chicago, where he later became Chief of Cardiology. [5] [4] He was elected to several honors societies, including Phi Beta Kappa and Alpha Omega Alpha. [6] Between 1982 and 1987, Leiden was a clinical fellow in cardiology at the Brigham and Women’s Hospital,the Harvard Medical School and a postdoctoral fellow in medicine at the Dana–Farber Cancer Institute. [7]

Career

In 1987, Leiden was appointed assistant professor of medicine and assistant investigator in the Howard Hughes Medical Institute at the University of Michigan in Ann Arbor. [8]

In 1992, Leiden moved to the University of Chicago as the Rawson Professor of Medicine and Pathology and chief of the Division of Cardiology. [9]

In 1996, Leiden, along with Elizabeth and Gary Nabel founded Cardiogene, a gene therapy company, which was subsequently acquired by Boston Scientific. [10]

In 1999, Leiden was appointed the Elkin Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of medicine at the Harvard Medical School. [7]

Leiden moved to Abbott Labs in June 2000, as senior vice president and chief scientific officer. Later that year, he was promoted to president and chief operating officer and oversaw all aspects of the company’s global pharmaceutical business, where he led the development and launch of Kaletra and Humira. [11] [12]

In 2006, Leiden joined Clarus Ventures as a managing director. [13] At Clarus, Leiden founded and chaired the boards of Lycera Corporation and Variation Biotechnologies, and served as chairman of the board of TyRx, Inc., which was subsequently acquired by Medtronic (NYSE :  MDT). [14]

Vertex

Leiden served as chairman, president and chief executive officer of Vertex from 2012 to 2020. Under his leadership, Vertex developed and launched Kalydeco, Orkambi, Symdeko and Trikafta – the first medicines to treat the underlying cause of cystic fibrosis. [15] The FDA approved Trikafta on October 21, 2019. [16]

In 2015 Leiden established a collaboration between Vertex and CRISPR Therapeutics that led to the discovery and development of Casgevy, (exagamglogene autotemcel; formerly known as CTX001), [17] the first gene editing treatment to show curative potential for two human genetic diseases, sickle cell disease and beta thalassemia. [18] [19] [20] Casgevy was approved for use in the UK (November 2023), the United States (January 2024) and Europe, (February 2024.) [21]

In 2015 Vertex shareholders voted to recommend reducing Leiden's compensation from its 2014 estimated figure of US$48.5 million. By 2017 his earnings totaled approximately US$17.3 million. [22] Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. [23] [24]

Criticism of Vertex pricing structures for Orkambi, a groundbreaking cystic fibrosis drug costing in the region of US$ 135,000 to US$ 270,000 [25] per patient per year depending on the patient's country, has resulted in campaigns by concerned parent groups addressed to Leiden. [26] [27] Leiden wrote to the UK Prime Minister Theresa May in 2018, suggesting Vertex might consider reducing investment in the UK as a result of the lack of agreement between Vertex and the UK's National Health Service on the pricing of a five-year access agreement for Vertex drugs. [28]

On October 24, 2019, Vertex reached an agreement with NHS England for all currently licensed Vertex cystic fibrosis medicines, [29] [30] [31] having previously reached similar agreements with countries including Scotland, Ireland and France. [32] [33] On June 20, 2024, the National Institute for Health and Care Excellence, (NICE) said in its final draft guidance that Orkambi, Symkevi, and Kaftrio are recommended for the treatment of Cystic Fibrosis, with Vertex coming to a long-term, extended, reimbursement agreement [34] with the NHS. [35] [36] [37] This final decision differs from its provisional draft guidance from November 2023 that recommended that the three drugs were above the acceptable range of NHS resources in terms of cost effectiveness, despite positive outcomes for Cystic Fibrosis patients. [38]

While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020. [39]

On April 1, 2020, Leiden transitioned to the role of executive chairman. He was succeeded by Reshma Kewalramani, who was previously the company's chief medical officer. Leiden currently serves as executive chairman. [40] [41] [42]

Boards and awards

He is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation and the Association of American Physicians. [43] [44] He currently serves as a lead independent director [45] of the Massachusetts Mutual Life Insurance Company, and was the former vice chairman of Shire Pharmaceuticals and was formerly a director of PathAI, Millennium Pharmaceuticals, Abbott Labs, Quest Diagnostics, and TAP Pharmaceuticals. [7] [46] Leiden is also the chairman of Casana, a home health monitoring company. [47] In May 2022 Leiden was appointed as Chairman of the Board of Odyssey Therapeutics, a company developing novel medicines for cancer and auto-immune disease. [48]

Leiden was named a Crain’s Chicago Business 40 Under 40 in 1994; and served as a member of the NHLBI Board of Scientific Counselors between 1994 and 1999. [7] [49] In 2000, he was president of the American Society for Clinical Investigation. [50]

In 2017, Ernst and Young named Leiden an Entrepreneur of the Year in Life Sciences. [51] In 2018, the Massachusetts Biotechnology Council awarded Leiden the Henri A. Termeer Innovative Leadership Award; and the Greater Boston Chamber of Commerce named Leiden to the Academy of Distinguished Bostonians. [52] [53] Leiden was also named one of Boston Business Journal’s Power 50 for several years, including most recently in 2022. [54] [55] In 2018 and 2020, he was named as part of Boston Magazine’s 100 Most Influential People in Boston [56] and was honored as a New Englander of the Year by the New England Council. [57] [58] In 2018 he was named “Best Biopharma CEO” by STAT News. [59] In December 2020 Jeffrey Leiden was honored with the Forbes Lifetime Achievement in BioPharma Award at the 2020 Forbes Healthcare Summit. [60]

Leiden also served in 2016 as co-chairman of the Massachusetts’s Governor’s Digital Healthcare Council; [61] is a member of the Governor's Task Force on Artificial Intelligence; [62] [63] [64] and the Governor’s STEM Advisory Council. [65]

In 2018 he was honored with the "New Englander of the Year Award" by the New England Council. [66] [67]

Leiden was ranked 13th on Forbes' list of most innovative leaders for 2019, the highest-ranking leader in the healthcare/biotech sector. [68]

He is trustee of the Boston Symphony Orchestra. [69]

Leiden is a member of the MIT Presidential CEO Advisory Board. [70]

In November 2022 Leiden was named as one of several strategic advisors for the newly launched Life Sciences Private Capital, a private equity division of J.P. Morgan. [71]

He is a director of the Massachusetts Competitive Partnership (MACP) and previously served as chair from January 2020 to December 2022. [72] [73]

Philanthropy

In December 2017, Leiden and his wife Lisa established a professorship in translational medicine at the Brigham and Women’s Hospital and Harvard Medical School. [74] The Leidens are also major donors to the Museum of Fine Arts, Boston, Ariadne Labs and the Bottom Line Foundation. [12] [75]

Related Research Articles

<span class="mw-page-title-main">Cystic fibrosis</span> Genetic disorder inhibiting clearance of mucus from the lungs

Cystic fibrosis (CF) is a genetic disorder inherited in an autosomal recessive manner that impairs the normal clearance of mucus from the lungs, which facilitates the colonization and infection of the lungs by bacteria, notably Staphylococcus aureus. CF is a rare genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. The hallmark feature of CF is the accumulation of thick mucus in different organs. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. Other signs and symptoms may include sinus infections, poor growth, fatty stool, clubbing of the fingers and toes, and infertility in most males. Different people may have different degrees of symptoms.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

Venture philanthropy is a type of impact investment that takes concepts and techniques from venture capital finance and business management and applies them to achieving philanthropic goals. The term was first used in 1969 by John D. Rockefeller III to describe an imaginative and risk-taking approach to philanthropy that may be undertaken by charitable organizations.

<span class="mw-page-title-main">Ivacaftor</span> Cystic fibrosis treatment drug

Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 4–5% cases of cystic fibrosis. It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.

Lumacaftor (VX-809) is a pharmaceutical drug that acts as a chaperone during protein folding and increases the number of CFTR proteins that are trafficked to the cell surface. It is available in a single pill with ivacaftor; the combination, lumacaftor/ivacaftor, is used to treat people with cystic fibrosis who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the defective protein that causes the disease. It was developed by Vertex Pharmaceuticals and the combination was approved by the FDA in 2015. As of 2015, lumacaftor had no medical use on its own.

<span class="mw-page-title-main">AbbVie</span> American pharmaceutical company

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">Lumacaftor/ivacaftor</span> Cystic fibrosis drug

Lumacaftor/ivacaftor, sold under the brand name Orkambi among others, is a combination of lumacaftor and ivacaftor used to treat people with cystic fibrosis who have two copies of the F508del mutation. It is unclear if it is useful in cystic fibrosis due to other causes. It is taken by mouth.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Editas Medicine</span> Discovery-phase pharmaceutical company

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

<span class="mw-page-title-main">Intellia Therapeutics</span> American biotechnology company

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

<span class="mw-page-title-main">Joshua Boger</span> Organic chemist and the founder of Vertex Pharmaceuticals

Joshua S. Boger is an organic chemist and the founder of Vertex Pharmaceuticals Incorporated. He is considered a pioneer in the field of structure-based rational drug design. Drugs developed include amprenavir, an HIV protease inhibitor; telaprevir, a protease inhibitor for treatment of hepatitis C; and Kalydeco, for the treatment of cystic fibrosis. In 2003, Vertex was listed as one of forty worldwide Technology Pioneers by the World Economic Forum. As of 2012, Boger became executive chairman of Alkeus Pharmaceuticals.

<span class="mw-page-title-main">Tezacaftor</span> Chemical compound

Tezacaftor is a drug used for the treatment of cystic fibrosis (CF) in people six years and older, who have a F508del mutation, the most common type of mutation in the CFTR gene. It is sold as a fixed-dose combination with ivacaftor under the brand name Symdeko. It was approved by the U.S. FDA in 2018. The combination of elexacaftor, tezacaftor, and ivacaftor is being sold as Trikafta.

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.

Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Peter Grootenhuis was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation. Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445), which in combination with Ivacaftor are the components of Trikafta, a drug approved by the FDA in 2019 to treat CF in more than 90% of CF patients. For Grootenhuis’ contributions to the discovery of these compounds, he was awarded the 2018 IUPAC Richter Prize, the American Chemical Society’s 2013 Heroes of Chemistry Award, and inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame. Grootenhuis has contributed to the discovery of over 11 clinical candidates, co-authored more than 100 peer reviewed papers and is inventor of 65 + U.S Patents, and more than 50 EU Patents.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

Paul Adrian Negulescu is an American–Romanian cell biologist. He is a Senior Vice President at American pharmaceutical company Vertex Pharmaceuticals. He received the 2022 Shaw Prize in Life science and medicine, together with Michael J. Welsh, for their work that uncovered the etiology of cystic fibrosis and developed effective medications.

Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Cerevel Therapeutics Holdings, Inc. is an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses.

References

  1. ↑ Joe Carlson (December 16, 2011). "Vertex names Leiden incoming CEO". Modern Healthcare.
  2. ↑ "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals Incorporated's Board of Directors". Biospace. July 8, 2009.
  3. ↑ "Jeffrey "Jeff" Leiden Chairman/President/CEO, Vertex Pharmaceuticals Inc". Bloomberg L.P. Retrieved May 12, 2018.
  4. 1 2 3 "First Rounders podcast: Jeffrey Leiden". Nature Biotechnology. 36 (3): 224. 2018-03-06. doi: 10.1038/nbt.4087 . ISSN   1546-1696. PMID   29509728.
  5. ↑ Arsenio Oloroso Jr. (September 24, 1994). "Jeffrey M. Leiden Section Chief of Cardiology University of Chicago Medical Center". Crain's Chicago Business.
  6. ↑ "Medicine on the Midway – Spring 2019". issuu. Retrieved 2019-07-02.
  7. 1 2 3 4 "Executive Profile Jeffrey Marc Leiden". Bloomberg L.P. Retrieved May 11, 2018.
  8. ↑ Hoffman, Michelle (December 6, 1991). "Putting new muscle into gene therapy". Science . 254 (5037): 1455–1456. Bibcode:1991Sci...254.1455H. doi:10.1126/science.1962203. PMID   1962203.
  9. ↑ Emily Mullin. "Jeffrey Leiden—Vertex Pharmaceuticals". FierceBiotech. Retrieved May 10, 2018.
  10. ↑ "Ins and Outs of Cardiovascular Gene Therapy; Cardiogene: The Insuide; Eurogene: The Outside". BioCentury. September 29, 1997.
  11. ↑ "Harvard cardiologist Jeffrey Leiden elected new chief scientific officer at Abbott Laboratories". Medscape. June 16, 2000.
  12. 1 2 "Jeffrey Leiden, M.D., Ph.D." Vertex Pharmaceuticals . Retrieved May 10, 2018.
  13. ↑ "Dr. Jeffrey Leiden Joins Clarus Ventures As Partner". Biospace. November 1, 2006.
  14. ↑ "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors". Evaluate. July 7, 2009.
  15. ↑ Matthew Herper (August 8, 2017). "For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another?". Forbes .
  16. ↑ Commissioner, Office of the (2019-10-24). "FDA approves new breakthrough therapy for cystic fibrosis". FDA. Retrieved 2019-10-25.
  17. ↑ Shapiro, Lindsey (17 May 2024). "Casgevy (exagamglogene autotemcel) for sickle cell disease". Sickle Cell Disease News.
  18. ↑ "1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive". NPR.org. Retrieved 2021-02-23.
  19. ↑ "Vertex reveals promising data from first CRISPR-treated patients". PMLive. 2019-11-20. Retrieved 2021-02-23.
  20. ↑ Smith, Jonathan (2019-06-07). "CRISPR Therapeutics and Vertex Pharmaceuticals Seal Deal Worth up to €890M". Labiotech.eu. Retrieved 2021-02-23.
  21. ↑ Barrie R (13 February 2024). "CRISPR gene therapy Casgevy secures approval in Europe". Pharmaceutical Technology.
  22. ↑ "BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln". Reuters. 2018-04-17. Retrieved 2019-05-29.
  23. ↑ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
  24. ↑ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.
  25. ↑ Thomas, Katie (2018-06-24). "A Drug Costs $272,000 a Year. Not So Fast, Says New York State". The New York Times. ISSN   0362-4331 . Retrieved 2019-02-03.
  26. ↑ Boseley S, ed. (2019-02-03). "Cystic fibrosis: the patients facing shorter lives due to drug's expense". The Guardian. ISSN   0261-3077 . Retrieved 2019-02-03.
  27. ↑ "CF Support Group | Letter to Dr Jeffrey Leiden". CF Support Group. Retrieved 2019-02-03.
  28. ↑ "Orkambi: Drugs maker says NHS 'undervalues' patient lives". Sky News. Retrieved 2019-02-03.
  29. ↑ "Vertex, NHS England and NICE finally reach agreement for Orkambi". PMLive. 2019-10-24. Retrieved 2019-10-25.
  30. ↑ "Vertex and the U.K. reach a deal for cystic fibrosis medicines". STAT. 2019-10-24. Retrieved 2019-10-25.
  31. ↑ "Cystic fibrosis drug deadlock 'must end'". 2019-02-04. Retrieved 2019-05-07.
  32. ↑ Bruce, Francesca. "Vertex Inks New Cystic Fibrosis Deals In Europe". Pink Sheet. Retrieved 3 April 2022.
  33. ↑ "Landmark NHS deal to open up access to life-changing cystic fibrosis drug". NHS. Retrieved 3 April 2022.
  34. ↑ Manalac, Tristan (21 June 2024). "Vertex Finally Reaches Pricing Deal With England's NHS for Cystic Fibrosis Drugs". BioSpace.
  35. ↑ Furlong, Ashleigh (20 June 2024). "Vertex Reaches Pricing Deal With NHS for Cystic Fibrosis Drugs". Bloomberg.
  36. ↑ Silverman, Ed (20 June 2024). "Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments". STAT.
  37. ↑ Inácio, Patricia (26 June 2024). "3 CFTR modulators guaranteed public reimbursement in England". Cystic Fibrosis News Today.
  38. ↑ Lipanovic, David (2023-11-14). "NICE does not recommend three cystic fibrosis drugs in draft guidance". The Pharmaceutical Journal. Retrieved 2024-02-25.
  39. ↑ Doler, Kathleen (16 July 2020). "How A Medical Brainiac CEO Turned Brilliance Into Billions".
  40. ↑ DeAngelis, Allison (25 July 2019). "Vertex CEO Jeff Leiden to step down". www.bizjournals.com. Retrieved 2019-07-31.
  41. ↑ "Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role". Endpoints News. Retrieved 2020-04-02.
  42. ↑ "Vertex Pharmaceuticals Incorporated Form 10-K" . Retrieved 3 April 2022.
  43. ↑ "Keynote Speakers". Massachusetts Institute of Technology. February 22, 2013.
  44. ↑ Pray, Leslie (August 14, 2007). Understanding the Benefits and Risks of Pharmaceuticals. National Academies Press. ISBN   9780309179768.
  45. ↑ "Corporate Governance". MassMutual. 2024.
  46. ↑ "STEM Council Co-Chairs". Massachusetts Department of Higher Education. Retrieved May 20, 2018.
  47. ↑ Jennings, Katie. "This Smart Toilet Seat Might Save Your Life One Day". Forbes. Retrieved 2021-02-11.
  48. ↑ "Odyssey Therapeutics:News". odysseytx.com/news. 24 May 2022.
  49. ↑ "40 Under 40 historical archive". Crain's Chicago Business. July 9, 2014.
  50. ↑ "The American Society for Clinical Investigation". Archived from the original on 2017-03-17. Retrieved 2019-07-15.
  51. ↑ "EY Announces Winners for the Entrepreneur Of The Year® 2017 New England Award". Ernst & Young. June 28, 2017.
  52. ↑ "MassBio to Honor Dr. Jeffrey Leiden with Henri A. Termeer Innovative Leadership Award". MassBio. March 6, 2018.
  53. ↑ "With $500m initiative, Baker is a biotech holdout no longer". Boston Globe. June 21, 2017.
  54. ↑ "Meet the 2022 Boston Business Journal Power 50 Movement Makers". Boston Business Journal. 16 November 2022.
  55. ↑ "Meet the 2018 Boston Business Journal Power 50". Boston Business Journal. October 9, 2018.
  56. ↑ "Power List: The 100 Most Influential Bostonians". Boston Magazine. 28 April 2020. Retrieved 2020-05-05.
  57. ↑ "2018 New Englanders of the Year Announced". The New England Council. Retrieved November 18, 2018.
  58. ↑ "The 100 Most Influential People in Boston". Boston Magazine. April 24, 2018.
  59. ↑ "Leiden victorious in best biopharma CEO tally; Alles tops worst list". STAT. 2018-12-18. Retrieved 2019-07-02.
  60. ↑ "A Tribute to Jeffrey Leiden: Forbes Lifetime Achievement in BioPharma Award | 2020 Forbes Healthcare Summit". Forbes. Retrieved 2020-12-15.
  61. ↑ Wood, Colin (22 November 2016). "Massachusetts announces Digital Healthcare Council". Statescoop.
  62. ↑ Solis, Steven (14 February 2024). "Massachusetts taps tech leaders, Boston officials for AI task force". Axios.
  63. ↑ "Massachusetts Establishes Task Force to Scale AI Adoption in the State". cdo magazine. 7 March 2024.
  64. ↑ "Governor Healey Signs Executive Order Establishing Artificial Intelligence (AI) Strategic Task Force". Mass.gov. 14 February 2024.
  65. ↑ "Healey-Driscoll Administration Announces 2024 STEM Summit". Mass.gov. 22 April 2024.
  66. ↑ "The New England Council Annual Dinner 2018". Conventures. 2018.
  67. ↑ "New England Council hosts annual New Englander of the Year awards". Bill Bret Boston. 13 October 2018.
  68. ↑ "America's Most Innovative Leaders". Forbes. Retrieved 2019-09-10.
  69. ↑ "Boston Symphony Orchestra concert program, Subscription Series, Season 139 (2019–2020), Week 6, page 5". collections.bso.org. Retrieved 2020-05-05.
  70. ↑ "Jeffrey Leiden, M.D., Ph.D." Vertex.
  71. ↑ Bayer, Max (3 November 2022). "J.P. Morgan's new life sciences private equity arm will be hottest ticket at firm's upcoming conference". Fierce Biotech.
  72. ↑ "MACP". masscompetes.org.
  73. ↑ "Jeffrey Leiden, MD, PhD". Vrtx.com.
  74. ↑ "Bench to Bedside". Harvard Medical School. November 1, 2017.
  75. ↑ "The Future is Now: New Investments". Museum of Fine Arts, Boston . Retrieved May 24, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.